Iksuda Therapeutics is creating next-generation, class leading Antibody-Drug Conjugates (ADCs).
Our ADCs target difficult-to-treat cancers, including those that are resistant or refractory to current therapies.
We are building a pipeline of ADCs centred on:
• PermaLink® – proprietary conjugation chemistry for improved ADC stability
• Novel ultra-potent toxins for improved tumour killing
• Novel antibodies targete...
Iksuda Therapeutics is creating next-generation, class leading Antibody-Drug Conjugates (ADCs).
Our ADCs target difficult-to-treat cancers, including those that are resistant or refractory to current therapies.
We are building a pipeline of ADCs centred on:
• PermaLink® – proprietary conjugation chemistry for improved ADC stability
• Novel ultra-potent toxins for improved tumour killing
• Novel antibodies targeted towards well-selected antigens associated
primarily with solid tumours
We are focused on providing more effective treatments for patients who have few options, with a particular focus on solid tumours
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.